Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.62
-1.3%		$74.06
$35.64
▼
$80.97
$6.70B0.24665,333 shs1.78 million shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.99
$71.39
$10.11
▼
$77.20
$1.63B2.621.86 million shsN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$91.83
-7.1%		$103.81
$63.23
▼
$130.00
$6.42B0.49532,173 shs1.80 million shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$94.96
-2.8%		$96.40
$14.89
▼
$115.51
$6.47B-0.34746,357 shs1.94 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.32%+3.14%-7.51%+22.17%+97.83%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%0.00%+0.12%+331.32%+543.73%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-7.07%-6.51%-10.18%-14.28%+25.55%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-2.83%+2.79%-13.43%+31.27%+485.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.62
-1.3%		$74.06
$35.64
▼
$80.97
$6.70B0.24665,333 shs1.78 million shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.99
$71.39
$10.11
▼
$77.20
$1.63B2.621.86 million shsN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$91.83
-7.1%		$103.81
$63.23
▼
$130.00
$6.42B0.49532,173 shs1.80 million shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$94.96
-2.8%		$96.40
$14.89
▼
$115.51
$6.47B-0.34746,357 shs1.94 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.32%+3.14%-7.51%+22.17%+97.83%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%0.00%+0.12%+331.32%+543.73%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-7.07%-6.51%-10.18%-14.28%+25.55%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-2.83%+2.79%-13.43%+31.27%+485.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.73
Moderate Buy$87.7817.63% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.00
Hold$71.67-6.91% Downside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$137.3149.53% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$133.0040.06% Upside

Current Analyst Ratings Breakdown

Latest FBRX, CGON, ORKA, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$120.00
9/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$137.00
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$137.00
8/14/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$200.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$165.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$151.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,637.21N/AN/A$9.33 per share8.00
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.66 per shareN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$521.31M11.44$0.05 per share1,938.44$6.12 per share15.00
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$9.69 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%11/13/2026 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$69.38M-$4.65N/AN/AN/AN/A-94.82%-77.68%11/13/2026 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$14.55N/AN/AN/A-139.18%-36.28%-8.54%11/3/2026 (Estimated)
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$2.03N/AN/AN/AN/A-21.65%-20.88%11/11/2026 (Estimated)

Latest FBRX, CGON, ORKA, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.9950-$0.97+$0.0250-$0.97N/AN/A
8/10/2026Q2 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.5125-$0.55-$0.0375-$0.55N/AN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
10.01
10.01
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.86
2.74
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
38.51
38.51

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
4.40%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
14288.64 million84.39 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
521.23 million20.30 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
43364.93 million59.53 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
6866.21 million50.66 millionN/A

Recent News About These Companies

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $234,680.92 in Stock
September 18 at 6:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031463
Arjun Agarwal Sells 9,459 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
September 17 at 4:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029295
Joana Goncalves Sells 7,947 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
September 17 at 4:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029294
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 560 Shares
September 16 at 5:52 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-orka-insider-buying-and-selling-2026-09-16/
Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 560 Shares of Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-oruka-therapeutics-nasdaq-orka-svp-arjun-agarwal-sells-560-shares-of-stock-2026-09-15/
Lawrence Otto Klein Sells 2,452 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-lawrence-otto-klein-sells-2452-shares-of-oruka-therapeutics-nasdaq-orka-stock-2026-09-15/
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares of Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-oruka-therapeutics-nasdaq-orka-insider-joana-goncalves-sells-7947-shares-of-stock-2026-09-15/
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 9,459 Shares of Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-oruka-therapeutics-nasdaq-orka-svp-sells-9459-shares-of-stock-2026-09-15/
Oruka (ORKA): EVERLAST-A 28+ Week Data Key Catalyst For ORKA-001 In Psoriasis
September 15, 2026  |  rttnews.comhttps://www.rttnews.com/3691222/oruka-orka-everlast-a-28-week-data-key-catalyst-for-orka-001-in-psoriasis.aspx
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of "Moderate Buy" by Brokerages
September 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31020050
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-oruka-therapeutics-inc-nasdaq-orka-given-average-rating-of-moderate-buy-by-brokerages-2026-09-13/
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)
September 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/JAZZ/pressreleases/4533127/analysts-are-bullish-on-top-healthcare-stocks-oruka-therapeutics-orka-jazz-pharmaceuticals-jazz/
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3359049/0/en/oruka-therapeutics-to-attend-the-2026-morgan-stanley-global-healthcare-conference.html
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Oruka Therapeutics, Inc. $ORKA
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-grows-stock-holdings-in-oruka-therapeutics-inc-orka-2026-09-07/
Q3 EPS Estimate for Oruka Therapeutics Lowered by Analyst
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-q3-eps-estimate-for-oruka-therapeutics-lowered-by-analyst-2026-09-07/
Legal & General Group Plc Purchases Shares of 30,198 Oruka Therapeutics, Inc. $ORKA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-purchases-shares-of-30198-oruka-therapeutics-inc-orka-2026-09-06/
HC Wainwright Reiterates "Buy" Rating for Oruka Therapeutics (NASDAQ:ORKA)
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-reiterates-buy-rating-for-oruka-therapeutics-nasdaq-orka-2026-09-03/
278,164 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Braidwell LP
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-278164-shares-in-oruka-therapeutics-inc-orka-acquired-by-braidwell-lp-2026-09-03/
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells 75,000 Shares of Stock
September 2, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-orka-insider-buying-and-selling-2026-09-02/
Bank of New York Mellon Corp Invests $13.41 Million in Oruka Therapeutics, Inc. $ORKA
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-invests-1341-million-in-oruka-therapeutics-inc-orka-2026-09-02/
Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 75,000 Shares
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-oruka-therapeutics-nasdaq-orka-ceo-lawrence-otto-klein-sells-75000-shares-2026-09-01/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$74.62 -1.00 (-1.32%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$72.49 -2.13 (-2.85%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)
As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$91.83 -6.99 (-7.07%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$92.88 +1.05 (+1.14%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$94.96 -2.77 (-2.83%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$95.00 +0.04 (+0.04%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas